BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1698731)

  • 21. Production of a recombinant human T-cell leukemia virus type-I trans-activator (tax1) antigen and its utilization for generation of monoclonal antibodies against various epitopes on the tax1 antigen.
    Tanaka Y; Yoshida A; Tozawa H; Shida H; Nyunoya H; Shimotohno K
    Int J Cancer; 1991 Jun; 48(4):623-30. PubMed ID: 1710610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I.
    Fujii H; Shimizu M; Miyagi T; Kunihiro M; Tanaka R; Takahashi Y; Tanaka Y
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26848684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people.
    Chen YM; Lee TH; Samuel KP; Okayama A; Tachibana N; Miyoshi I; Papas TS; Essex M
    J Virol; 1989 Nov; 63(11):4952-7. PubMed ID: 2677406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
    Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
    Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
    Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune complex transfer enzyme immunoassay for (anti-human T-cell leukemia virus type I) IgG in serum using a synthetic peptide, Env gp46(188-209), as antigen.
    Kohno T; Sakoda I; Ishikawa E
    J Clin Lab Anal; 1991; 5(1):25-37. PubMed ID: 1900332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.
    Londos-Gagliardi D; Dalibart R; Geoffre S; Dalbon P; Pouliquen JF; Georges-Courbot MC; Sainte-Foie S; Hajjar C; Georges AJ; Moreau JP; Guillemain B
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):941-50. PubMed ID: 8798979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
    Kaumaya PT; Conrad SF; DiGeorge AM; Lairmore MD
    Leukemia; 1995 Oct; 9 Suppl 1():S133-8. PubMed ID: 7475306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
    Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
    Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of an antigen shared by human thymic epithelium and human T cell leukemia virus p19 Gag protein.
    Palker TJ; Singer KH; Vahlne A
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jan; 11(1):10-9. PubMed ID: 8528727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.
    Papsidero LD; Dittmer RP; Vaickus L; Poiesz BJ
    J Clin Microbiol; 1992 Feb; 30(2):351-8. PubMed ID: 1371516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
    Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
    J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
    Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
    J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mother-to-child transmission of human T-cell lymphotropic virus type I (HTLV-I) in Jamaica: association with antibodies to envelope glycoprotein (gp46) epitopes.
    Wiktor SZ; Pate EJ; Murphy EL; Palker TJ; Champegnie E; Ramlal A; Cranston B; Hanchard B; Blattner WA
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1162-7. PubMed ID: 7692038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.